Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.
The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).
Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.
Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.